Summary
PNC Financial Services Group, Inc. (PNC) has filed an 8-K report detailing the establishment and public offering of its new 3.400% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series T. This new series of preferred stock, represented by depositary shares, ranks senior to common stock and equally with other existing preferred stock series regarding dividends and liquidation. The issuance is part of PNC's ongoing capital management strategy, providing additional capital while offering investors a new fixed-income security. The Series T Preferred Stock features a fixed dividend rate of 3.400% annually until September 15, 2026, after which the rate will reset every five years based on the five-year U.S. Treasury rate plus a spread of 2.595%. Dividends are non-cumulative, meaning missed payments do not accrue. The stock has a liquidation preference of $100,000 per share and is redeemable at PNC's option under specific conditions, including after the initial reset date or following a regulatory capital treatment event. This issuance aims to strengthen PNC's capital structure and provide flexibility for future strategic initiatives.
Key Highlights
- 1PNC established a new series of preferred stock: 3.400% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series T.
- 2The company completed a public offering of 1,500,000 depositary shares, each representing a 1/100th interest in a share of Series T Preferred Stock.
- 3The Series T Preferred Stock has a fixed dividend rate of 3.400% per annum until September 15, 2026.
- 4Post-2026, the dividend rate will reset every five years to the prevailing five-year U.S. Treasury rate plus a spread of 2.595%.
- 5Dividends are non-cumulative, meaning any missed dividend payments are not carried forward.
- 6The Series T Preferred Stock ranks senior to PNC's common stock and equally with other parity preferred stock.
- 7PNC has the option to redeem the Series T Preferred Stock under specific circumstances, including after the first reset date or following a regulatory capital treatment event.